The hospitalization burden of inflammatory bowel disease in China: a nationwide study from 2013 to 2018

He, Yiming; Mao, Ren; Yuan, Gang; Liu, Ruiming; Long, Jianyan; Ye, Xiao-Qi; Iacucci, Marietta; Ghosh, Subrata; Ben‐Horin, Shomron; Kaplan, Gilaad G.; He, Yao; Sung, Joseph J.Y.; Peng, Sui; Wang, Haibo; Chen, Minhu

doi:10.1177/17562848221102307

Cited by 11 publications

(13 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…He et al gathered hospitalization data for patients with IBD in China from the Hospital Quality Monitoring System (HQMS) database from 2013 to 2018. According to their study, hospitalization rates of IBD patients increased from 2.20 (95% CI = 2.17, 2.22) to 3.62 (3.59, 3.65) per 100,000 inhabitants, and hospitalization costs associated with IBD reached $426 million in 2018 ( 33 ). The insufficient health care coverage system and uneven medical conditions exacerbate the financial pressures and difficulties in accessing health care faced by IBD patients ( 34 ).…”

Section: Discussionmentioning

confidence: 99%

Long-term trends in the burden of inflammatory bowel disease in China over three decades: A joinpoint regression and age-period-cohort analysis based on GBD 2019

Zhang

Liu

Han

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundTo study the corresponding strategies to control inflammatory bowel disease (IBD), a comprehensive assessment of the disease burden is required. Herein, we present long-term trends in the burden of IBD in China over the last three decades, as well as its epidemiological features.MethodsWe characterized the burden of IBD in China using the GBD 2019 methods and results, based on prevalence, incidence, mortality, years lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) estimated using the DisMod-MR 2-1. We also used joinpoint and age-period-cohort (apc) analysis methods to interpret IBD epidemiological characteristics and compare them to global prevalence trends.ResultsThe age-standardized incidence and mortality rates in both sexes changed from 1.47 (95% CI: 1.24, 1.74) to 3.01 (95% CI: 2.59, 3.50) and from 0.86 (95% CI: 0.59, 1.16) to 0.30 (95% CI: 0.24, 0.35) per 100,000 people in China from 1990 to 2019. The age-standardized DALY rate in China decreased from 24.47 (95% CI: 17.88, 30.19) per 100,000 people in 1990 to 13.10 (95% CI: 10.29, 16.31) per 100,000 people in 2019. The average annual percentage change (AAPC) in age-standardized incidence, prevalence, and mortality rates for IBD in China were 2.51 (95% CI: 2.44, 2.57), 2.53 (95% CI: 2.41, 2.66), and −3.62 (95% CI: −3.85, −3.39). The effects of age, period, and cohort on incidence and mortality rates differed.ConclusionsThe increasing age-standardized prevalence rates are contributed to by the reduction in age-standardized mortality rates and DALYs, compounded by the rise in the age-standardized incidence rates between 1990 and 2019 in China. The burden of IBD in China will be a major public health challenge, given the country's large population base and aging population.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term trends in the burden of inflammatory bowel disease in China over three decades: A joinpoint regression and age-period-cohort analysis based on GBD 2019

Zhang

Liu

Han

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…In recent years, the increasing hospitalization rates of patients with CD in China have caused a heavy economic burden [2]. A study conducted in China in a nationwide database showed that from 2013 to 2018, the hospitalization rates for CD in China increased from 2.20 to 3.62 per 100,000 individuals with an annual percentage of change of 10.68%, and the hospital charges for CD patients were $1631.15 (interquartile range (IQR) = $2230.79) in 2018 [2]. Because there are no specific clinical manifestations in the early stages of CD, its diagnosis is based on endoscopy, pathology, imaging and other comprehensive diagnoses, resulting in difficulties and delays in diagnosis [3].…”

Section: Introductionmentioning

confidence: 99%

“…Previous studies suggested that CD involved an inflammatory response caused by the combined action of multiple factors such as genetic susceptibility, environmental factors, gut microbes and immune responses [1]. In recent years, the increasing hospitalization rates of patients with CD in China have caused a heavy economic burden [2]. A study conducted in China in a nationwide database showed that from 2013 to 2018, the hospitalization rates for CD in China increased from 2.20 to 3.62 per 100,000 individuals with an annual percentage of change of 10.68%, and the hospital charges for CD patients were $1631.15 (interquartile range (IQR) = $2230.79) in 2018 [2].…”

Section: Introductionmentioning

confidence: 99%

Clinical validation of serum immunosignatures in early diagnosis of Crohn's disease

Ma,

Zhang,

Wang

et al. 2023

iLABMED

View full text Add to dashboard Cite

BackgroundThe search for biomarkers suitable for early diagnosis of Crohn's disease (CD) is challenging. This study investigated the efficacy of serological markers for the early diagnosis of CD.MethodsThis was a retrospective nested cohort study. Indirect immunofluorescence and enzyme‐linked immunosorbent assay were used to detect ASCA IgG, ASCA IgA, AYMA IgG, AYCA IgG, FI2Y IgG, p‐ANCA IgG, GAB IgG and PAB IgG in patient serum samples.ResultsThe positive rates of ASCA IgG, ASCA IgA, AYMA IgG, AYCA IgG, FI2Y IgG, p‐ANCA IgG, GAB IgG and PAB IgG in patients with early CD, advanced CD and other intestinal diseases were 37.0% versus 56.8% versus 27.8%; 3.7% versus 20.5% versus 19.4%; 14.8% versus 2.3% versus 2.8%; 25.9% versus 9.1% versus 8.3%; 18.5% versus 15.9% versus 8.3%; 0.0% versus 2.8%, 18.5%; 13.6% versus 18.2% versus 16.7%; and 7.4% versus 20.5% versus 0.0%, respectively. The positive rates of ASCA IgG, AYCA IgG and PAB IgG were significantly different among the three groups (p < 0.05). In 85.2% of early CD patients, at least one antibody was detected 1 year before diagnosis. The sensitivity of the ASCA/AYMA/AYCA/FI2Y/GAB combination for early diagnosis was 85.2%. The sensitivity of the ASCA/AYMA/AYCA/FI2Y/GAB/PAB/PANCA combination for differentiating CD from other diseases was 87.3%.ConclusionsASCA IgG and AYCA IgG have potential value in identifying the course of CD. AYCA IgG may be a potential marker for the early diagnosis of CD, and ASCA IgG indicates an advanced stage. The combination of ASCA, AYMA, AYCA, FI2Y, and GAB improves early diagnostic accuracy of CD.

show abstract

“…Inflammatory bowel disease (IBD) is a chronic inflammatory gastrointestinal disorder, which affects 6.8 million people globally [ 1 ]. In China, the absolute number of hospitalized patients with IBD is estimated to reach 166,000 in 2018 [ 2 ]. Moreover, about one-third of patients with IBD develop a strictured disease phenotype during their lifetime [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

ELMO1 ameliorates intestinal epithelial cellular senescence via SIRT1/p65 signaling in inflammatory bowel disease-related fibrosis

Chen,

Li,

et al. 2023

Gastroenterology Report

View full text Add to dashboard Cite

Background Intestinal fibrosis is a common complication in inflammatory bowel disease (IBD), which still lacks of reliable markers and therapeutic options. Cellular senescence has been considered an important mechanism of intestinal fibrosis, but the underlying molecular link remains elusive. Methods Tissues were stained using α-smooth muscle actin (α-SMA), fibronectin, and collagen I as markers of myofibroblastic differentiation. Cellular senescence was confirmed through Lamin B1 staining, senescence-associated β-galactosidase staining, and the expression of senescence-associated secretory phenotype (SASP) factors. We explored the relationship between senescence of intestinal epithelial cells (IECs) and intestinal fibrosis, as well as the molecular mechanism underlying this interaction. The effects of irisin on cellular senescence and fibrosis were determined. Results Here, we identify engulfment and cell motility protein 1 (ELMO1) as a novel biomarker for intestinal cellular senescence and fibrosis. In fibrostrictured tissues from patients and murine models with IBD, significantly high levels of cellular senescence score and factors were noted, which positively correlated with the fibrotic regulator fibronectin. Senescent IECs, not fibroblast itself, released SASP factors to regulate fibroblast activation. Prolonging exposure to severe and persistent injurious stimuli decreased ELMO1 expression, which dampened SIRT1 deacetylase activity, enhanced NF-κB (p65) acetylation, and thereby accelerated cellular senescence. Deletion of ELMO1 led to senescent IECs accumulation and triggered premature fibrosis in murine colitis. Furthermore, irisin, inhibiting the degradation of ELMO1, could downregulate p65 acetylation, reduce IECs senescence, and prevent incipient intestinal fibrosis in murine colitis models. Conclusions This study reveals ELMO1 downregulation is an early symbol of intestinal senescence and fibrosis, and the altered ELMO1-SIRT1-p65 pathway plays an important role in intestinal cellular senescence and IBD-related fibrosis.

show abstract

The hospitalization burden of inflammatory bowel disease in China: a nationwide study from 2013 to 2018

Cited by 11 publications

References 43 publications

Long-term trends in the burden of inflammatory bowel disease in China over three decades: A joinpoint regression and age-period-cohort analysis based on GBD 2019

Long-term trends in the burden of inflammatory bowel disease in China over three decades: A joinpoint regression and age-period-cohort analysis based on GBD 2019

Clinical validation of serum immunosignatures in early diagnosis of Crohn's disease

ELMO1 ameliorates intestinal epithelial cellular senescence via SIRT1/p65 signaling in inflammatory bowel disease-related fibrosis

Contact Info

Product

Resources

About